Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can a cheap pill fix stiff arteries in insulin resistance?

NCT ID NCT03837626

First seen Sep 30, 2025 · Last updated Jun 23, 2026 · Updated 27 times

Summary

This study tested whether amiloride, a drug that blocks a salt-regulating protein called ENaC, can improve artery flexibility in overweight or obese adults with insulin resistance. 137 participants took either amiloride or a placebo daily for 6 months. The main goal was to measure arterial stiffness using a gold-standard test. The results could help develop new ways to protect heart health in people with metabolic syndrome.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INSULIN RESISTANCE are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • University of Missouri Hospital and Clinics

    Columbia, Missouri, 65201, United States

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Amiloride (a pill that blocks ENaC, a protein involved in salt balance)

What this could lead to

If it works, this could point toward a treatment to reduce arterial stiffness and improve heart health in people with insulin resistance.

What could go wrong

This is a small, completed Phase 2/3 trial. Results may not apply to everyone, and amiloride can cause side effects like electrolyte imbalances. The benefit may be modest.

Conditions

The condition(s) this trial relates to.

Insulin Resistance Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.